Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9752W HIGH $1.95
Volume
568.05 K
Value Traded
193.63 K
Short % Float
6.12%
-3.38%Week
-13.04%1 Month
-10.71%3 Month
-21.88%6 Month
-96.03%5 Year
-95.16%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
61.92 M
EPS (TTM)
-1.49
P/E Ratio
-
Ent. Value
-96.18 M
Total Shares
61.91 M
Float Shares
60.29 M
Insiders
2.64%
Institutions
77.78%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
PLRX Catalyst Timeline
Dated clinical, regulatory and corporate events for Pliant Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pliant Therapeutics, Inc.
364Total events
4Upcoming
70Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Fast Track DesignationPLN-101095Designation
FDA grants Fast Track designation for PLN-101095 in combination with pembrolizumab
solid tumors that are resistant to immune checkpoint inhibitorssource ↗
●Management ChangeCorporate
Appointed Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
◆Poster PresentationPLN-101095Presentation
Cohort Expansion of a Phase I Study of PLN-101095 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune Checkpoint Inhibitors
ICI-refractory advanced or metastatic solid tumorssource ↗
◆Oral PresentationPresentation
Pliant Therapeutics to participate in RBC Capital Markets Global Healthcare Conference fireside chat
▲First Patient DosedPLN-101095Trial
First patient dosed in FORTIFY Phase 1b indication expansion trial of PLN-101095 in combination with pembrolizumab
ICI-refractory advanced or metastatic solid tumorssource ↗
▲Oral PresentationPLN-101095Presentation
Oral presentation of updated Phase 1 data at AACR 2026
ICI-refractory advanced or metastatic solid tumorssource ↗
▲Trial InitiationPLN-101095Trial
Phase 1b indication expansion trial initiated
NSCLC, tumors with high tumor mutational burden, clear cell renal cell carcinomasource ↗
◆Enrollment UpdatePLN-101095Trial
Phase 1b indication expansion trial enrolling
NSCLC, tumors with high TMB, clear cell renal cell carcinomasource ↗
◆Oral PresentationPLN-101095Presentation
Phase 1 data oral presentation at AACR Annual Meeting 2026
checkpoint inhibitor refractory solid tumorssource ↗
◆Poster PresentationPLN-101095Presentation
Phase 1 data poster presentation at AACR Annual Meeting 2026
checkpoint inhibitor refractory solid tumorssource ↗
▲First Patient DosedPLN-101095Trial
First participant dosed in FORTIFY Phase 1b indication expansion trial
ICI-refractory advanced or metastatic solid tumorssource ↗
▲Oral PresentationPLN-101095Presentation
Oral presentation at AACR 2026 of updated Phase 1 data showing deepening of confirmed responses
ICI-refractory advanced or metastatic solid tumorssource ↗
◆Topline ReadoutbexotegrastClinical Data
BEACON-IPF Phase 2b topline data anticipated in mid-2026
idiopathic pulmonary fibrosissource ↗
▲Trial InitiationPLN-101095Trial
Initiation of Phase 1b indication expansion trial
NSCLC, clear cell renal cell carcinoma, tumors with high tumor mutational burdensource ↗
◆Oral PresentationPresentation
Pliant Therapeutics to participate in fireside chat at Oppenheimer Healthcare Life Sciences Conference
●PublicationbexotegrastPresentation
INTEGRIS-PSC results published in Journal of Hepatology
primary sclerosing cholangitissource ↗
◆Oral PresentationPresentation
Pliant Therapeutics to participate in fireside chat at Piper Sandler Healthcare Conference
▲Topline ReadoutPLN-101095Clinical Data
Interim data from Phase 1 dose escalation trial of PLN-101095 in combination with pembrolizumab
immune checkpoint inhibitor-refractory advanced solid tumorssource ↗
▲Topline ReadoutPLN-101095Clinical Data
Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors
checkpoint inhibitor refractory solid tumorssource ↗
◆Topline ReadoutPLN-101095Clinical Data
Oncology program data expected in Q4 2025
solid tumorssource ↗
●Trial CompletionbexotegrastTrial
BEACON-IPF close out activities to be completed in Q4 2025
idiopathic pulmonary fibrosissource ↗
▼Trial DiscontinuedbexotegrastTrial
Discontinued development of bexotegrast in IPF after unfavorable risk-benefit profile
idiopathic pulmonary fibrosissource ↗
▲First Patient DosedPLN-101095Trial
Phase 1 trial of PLN-101095 continues to enroll; dosing fifth cohort at 2000 mg BID
solid tumorssource ↗
▼Program DiscontinuationbexotegrastCorporate
Development of bexotegrast in IPF discontinued
idiopathic pulmonary fibrosissource ↗
◆Enrollment UpdatePLN-101095Trial
PLN-101095 Phase 1 trial currently enrolling fifth of five planned dose cohorts
solid tumors resistant to immune checkpoint inhibitorssource ↗
▼Restructuring LayoffsCorporate
Strategic restructuring of workforce and cost-saving measures announced in May, largely complete by end of Q2 2025
◆Poster PresentationPresentation
Plasma Proteome Analysis Reveals Shared and Unique Biomarkers of ILD Subtypes
interstitial lung diseasesource ↗
◆Poster PresentationbexotegrastPresentation
Single-Cell Profiling Demonstrates the Antifibrotic Effects of Bexotegrast on Pathologic Lung Cell Populations in the Presence and Absence of Background Therapy
idiopathic pulmonary fibrosissource ↗
◆Oral PresentationbexotegrastPresentation
Characterizing the Antifibrotic Activity of Bexotegrast on Distinct Fibroblast Populations in PCLS From Multiple ILD Subtypes
idiopathic pulmonary fibrosissource ↗
◆Oral PresentationbexotegrastPresentation
Oral presentation on antifibrotic activity of bexotegrast in PCLS from multiple ILD subtypes at ATS 2025
interstitial lung disease (ILD)source ↗
◆Poster PresentationPresentation
Poster presentation on plasma proteome analysis revealing biomarkers of ILD subtypes at ATS 2025
interstitial lung disease (ILD)source ↗
◆Poster PresentationbexotegrastPresentation
Poster presentation on single-cell profiling of bexotegrast effects on lung cell populations at ATS 2025
interstitial lung disease (ILD)source ↗
▲Interim AnalysisPLN-101095Trial
Interim Phase 1 data of PLN-101095 with pembrolizumab showed confirmed partial responses
solid tumors resistant to immune checkpoint inhibitorssource ↗
●Enrollment UpdatePLN-101095Trial
Enrolling fourth of five cohorts in Phase 1 dose escalation trial of PLN-101095
solid tumors resistant to immune checkpoint inhibitorssource ↗
▲PublicationbexotegrastPresentation
Phase 2a PET imaging trial results published in AJRCCM
idiopathic pulmonary fibrosissource ↗
▼Restructuring LayoffsCorporate
Strategic realignment with ~45% workforce reduction announced May 1, 2025
◆Topline ReadoutbexotegrastClinical Data
Topline data from BEACON-IPF trial
idiopathic pulmonary fibrosissource ↗
▲Topline ReadoutPLN-101095Clinical Data
Interim Phase 1 data for PLN-101095 in combination with pembrolizumab
immune checkpoint inhibitor-refractory advanced solid tumorssource ↗
◆Enrollment UpdatePLN-101095Trial
Enrolling fourth of five potential cohorts
immune checkpoint inhibitor-refractory advanced solid tumorssource ↗
Past FDA Catalysts and PDUFA Decisions
How PLRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | bexotegrast (PLN-74809) | Phase 2b/3 data readout | Phase 2b/3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D33 / 100
Pipeline Score
$69M
Pipeline Value
Fair Value
Valuation Signal
3
Drugs Scored
1.1x
rNPV / MCap
Top 61%
Micro Cap(rank 402 of 658)
Percentile Rank
Pliant Therapeutics, Inc. faces pipeline headwinds (33/100), with $275M risk-adjusted pipeline value, led by PLN-101095 in Advanced or Metastatic Solid Tumor (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PLN-101095 Small moleculeNCT06270706 | Advanced or Metastatic Solid Tumor | Phase 1 | RECRUITING | 124 | Jun 1, 2030 |
Clinical Trial Results
Readouts, endpoints and source filings for every PLRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PLN-101095 Fast Track | checkpoint inhibitor-refractory solid tumors | Phase 1b | 2026-05-11 | one confirmed overall complete response; two confirmed overall partial responses; one unconfirmed partial response; large increases in plasma interferon gamma (IFN- ) after 14 days of monotherapy; all responders maintained more than a 2-fold increase in IFN- at Week 10Read More | Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featurRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Iannone RobertDirector | Grant/Award | 60,000 60,000 held | $0.00 | 07/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PLRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.3 % (-25 %) | 7.00 M | 6.14 M | -0.03% ( -1.87 K) |
PLRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PLRX ranks across every disease it competes in
Competitive Position is a premium feature
See how PLRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPLRX News
PLRXPliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Pliant Therapeutics has appointed Dr. David Raben as Chief Medical Officer, bringing over 30 years of experience in oncology drug development. His expertise is expected to enhance the advancement of Pliant's lead program, PLN-101095, which targets ICI-refractory advanced solid tumors. Dr. Raben's previous roles include significant positions at Bicara Therapeutics and Amgen.
Read more →PLRXPliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
Pliant Therapeutics has received FDA Fast Track designation for PLN-101095, an oral dual selective inhibitor targeting integrins, in combination with pembrolizumab. This designation aims to expedite the development of treatments for solid tumors resistant to immune checkpoint inhibitors. The drug is currently being evaluated in the Phase 1a/1b FORTIFY trial, with results anticipated in 2027.
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Pliant Therapeutics has reported strong enrollment in its Phase 1b trial for PLN-101095, indicating positive momentum in its clinical development. Additionally, the company has strengthened its leadership by appointing seasoned oncology experts Flavia Borellini and Robert Iannone to its Board of Directors. These developments reflect Pliant's commitment to advancing its therapeutic pipeline.
Read more →PLRXPliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
Pliant Therapeutics has appointed Flavia Borellini, Ph.D., and Robert Iannone, M.D., M.S.C.E., to its Board of Directors. Both appointees bring extensive experience in oncology drug development and regulatory affairs. Borellini has a history of leading successful oncology drug launches, while Iannone has significant expertise in clinical operations. Their appointments are expected to strengthen Pliant's strategic direction as it advances its lead program, PLN-101095.
Read more →PLRXPliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Pliant Therapeutics announced a presentation at the 2026 ASCO Annual Meeting, highlighting their Phase 1b trial of PLN-101095. This trial focuses on patients with ICI-refractory solid tumors, specifically non-small cell lung cancer and clear cell renal cell carcinoma. The study evaluates the safety and efficacy of PLN-101095 in combination with pembrolizumab.
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Pliant Therapeutics provided a corporate update and reported positive first quarter 2026 financial results, including dosing the first participant in the FORTIFY Phase 1b trial of PLN-101095. The company also presented updated Phase 1 trial data at AACR 2026, indicating encouraging anti-tumor activity in checkpoint inhibitor-refractory patients. PLN-101095, a dual selective integrin inhibitor, is designed to enhance immune response in tumors. Despite a reduced net loss, Pliant faces risks related to trial enrollment and drug development timelines.
Read more →PLRXPliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
Pliant Therapeutics will participate in the 2026 RBC Capital Markets Global Healthcare Conference. CEO Bernard Coulie and CFO Keith Cummings will engage in a fireside chat on May 19, 2026. The event will be accessible via a live webcast, with a replay available for 30 days. Pliant focuses on integrin-based therapeutics, particularly PLN-101095 for treating advanced solid tumors.
Read more →PLRXPliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
Pliant Therapeutics has initiated the FORTIFY Phase 1b trial by dosing its first patient with PLN-101095, an oral dual selective integrin inhibitor, in combination with pembrolizumab. This trial targets patients with ICI-refractory advanced or metastatic solid tumors, focusing on safety and preliminary anti-tumor activity. Enrollment is currently underway, with interim data expected in 2027.
Read more →PLRXPliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics presented updated data from its Phase 1 trial of PLN-101095 at the AACR 2026 Annual Meeting. The trial showed promising results in ICI-refractory solid tumors, with confirmed responses and significant tumor reduction. The company has initiated a Phase 1b trial to further explore this combination therapy.
Read more →PLRXPliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics has announced the upcoming presentation of data from its Phase 1 clinical trial of PLN-101095 at the AACR Annual Meeting in April 2026. The presentation will occur during the Clinical Trials Mini Symposium and will be delivered by Dr. Timothy A. Yap from the University of Texas, M.D. Anderson Cancer Center. PLN-101095 is a novel dual integrin inhibitor aimed at addressing checkpoint resistance in advanced solid tumors. This presentation marks a significant step for Pliant as they evaluate the drug's safety and potential efficacy.
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
Pliant Therapeutics reported a corporate update and financial results for Q4 2025, highlighting the promising Phase 1 data for PLN-101095, which demonstrated significant antitumor activity in patients with checkpoint inhibitor refractory tumors. The company is initiating a Phase 1b trial to expand PLN-101095's indications based on encouraging response data. Financially, Pliant reduced its net loss compared to the previous year and maintains a strong cash position to support future operations. The ongoing trial data will be presented at the AACR Annual Meeting in April 2026.
Read more →PLRXPliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
Pliant Therapeutics, a clinical-stage biotechnology company, will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026. CEO Bernard Coulie and CFO Keith Cummings will host a fireside chat on February 25 at 2:40 p.m. ET. The event will be accessible via a live webcast, with a replay available for 30 days.
Read more →PLRX▼ -14.9%on this news
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
Pliant Therapeutics has reported promising interim data for its investigational drug PLN-101095, which is being evaluated in patients with immune checkpoint inhibitor-refractory advanced solid tumors. The drug demonstrated significant antitumor activity, with one complete response and three partial responses among the participants, and showed stable disease or tumor reduction in 60% of patients. The company plans to accelerate development with a Phase 1b trial set to begin in 2026. The positive results support the potential of PLN-101095 as a novel treatment for patients with challenging cancers.
Read more →PLRXPliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
Pliant Therapeutics, a clinical-stage biotechnology company, will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025. Key executives, including the CEO and CFO, will host a fireside chat on December 4 at 12:30 p.m. ET. The event will be accessible via a live webcast, with a replay available for 90 days.
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Pliant Therapeutics provided a corporate update and reported its third quarter 2025 financial results. The company is advancing its oncology program with data expected in the fourth quarter of 2025 and is completing close-out activities for the BEACON-IPF trial. Additionally, Pliant has received regulatory clearance for a Phase 1 study of PLN-101325, targeting muscular dystrophies.
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Pliant Therapeutics provided a corporate update and reported its second quarter 2025 financial results. The company announced the discontinuation of the bexotegrast development for idiopathic pulmonary fibrosis, citing an unfavorable risk-benefit profile. While restructuring efforts have largely been completed to maintain cash runway, the company expects to share additional data from its Phase 1 trial of PLN-101095 for solid tumors by the end of the year. Overall, the financial results showed a decrease in net loss but highlighted ongoing challenges in their drug development pipeline.
Read more →PLRX▼ -7.2%on this news
Pliant Therapeutics Provides Update on BEACON-IPF
Pliant Therapeutics has announced the discontinuation of bexotegrast development in idiopathic pulmonary fibrosis (IPF) following an unfavorable risk-benefit analysis from the BEACON-IPF trial. The decision was made after recommendations from the Data Safety Monitoring Board due to increased risks of adverse events. Despite this setback, Pliant continues to advance its oncology programs, including PLN-101095, which is currently in Phase 1 trials.
Read more →PLRXPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
Pliant Therapeutics showcased clinical and preclinical data at the ATS 2025 Conference. Key presentations highlighted the antifibrotic effects of bexotegrast on various fibroblast populations and identified biomarkers relevant to interstitial lung disease (ILD). The findings suggest potential advancements in treatment options and clinical strategies for ILD patients.
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Pliant Therapeutics has provided a corporate update and reported its financial results for Q1 2025, highlighting ongoing activities related to the BEACON-IPF trial. The company anticipates topline data from this trial in the second quarter of 2025. In addition, initial results from its oncology program with PLN-101095 show partial tumor responses among patients. However, the company faces challenges including a rising net loss and a significant workforce reduction aimed at extending its financial runway for future clinical trials.
Read more →About Pliant Therapeutics, Inc.
Headquarters331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next PLRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime